If you are considering this type of treatment, Amgen has started “The Prolia Post-marketing Active Safety Surveillance Program which is available to collect information from the prescribers on specific adverse events. For more information see http://www.proliasafety.com/ or call -800-772-6436 for information about this program (Prolia Prescribing Information, June 2, 2010).”
Prolia also has a shorter half-life, compared to the bisphosphonates at a mean half-life of 25.4 days.
Patients receiving Xgeva (denosumab), cannot take Prolia.
The approximate cost is $825.00 per injection.
How Prolia Works:
“Prolia (denosumab) is the first FDA-approved RANK Ligand inhibitor. Prolia targets and binds to RANK Ligand, inhibiting osteoclast formation, function and survival. Thus, Prolia can help keep osteoclasts from resorbing bone.”
- Prolia Prescribing Information, 2010 June 2; 1-30. http://pi.amgen.com/united_states/prolia/prolia_pi.pdf
- Am Fam Physician. 2002 Jul 1; 66(1):119-24. http://www.ncbi.nlm.nih.gov/pubmed/12126026?dopt=Abstract#